Minimizing adverse experience associated with oxybutynin therapy

摘要

The present invention relates to use of oxybutynin for the preparation of a topical formulation for administration to a mammal to provide a plasma area under the curve (AUC) ratio of oxybutynin to N-desethyloxybutynin of about 0.5:1 to about 5:1 to minimize an adverse drug experience associated with oxybutynin therapy wherein said topical formulation is selected from the group consisting of: ointments, lotions, pastes, mousses, aerosols and skin creams.